Core Insights - IDEXX Laboratories, Inc. is recognized as one of the top healthcare equipment stocks favored by hedge funds, indicating strong institutional interest in the company [1] - Recent analyst ratings have shown a downward revision in target prices, with Piper Sandler reducing it from $775 to $750, reflecting an 18% upside potential, while BTIG lowered it from $830 to $800, indicating a 26% upside potential [1][2] - The company's fourth quarter performance exceeded expectations in terms of revenue and profitability, although management's guidance for 2026 has raised some concerns, particularly regarding a projected decline in pet visits by 200 basis points [3] Company Overview - IDEXX Laboratories develops and sells diagnostic products for veterinary, livestock, poultry, and water microbiology testing, operating in 175 countries [4] - The company focuses on generating recurring revenues with high margins by placing diagnostic instruments and consumables in veterinary clinics [4]